FIB-116(FIB-116) - _专利_临床

概要

基本信息

药物类型

生物药

别名

靶点-

作用方式-

作用机制-

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

银屑病

原研机构

Ferrer Internacional SA

在研机构-

非在研机构

Ferrer Internacional SA

权益机构-

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 FIB-116 相关的临床结果

登录后查看更多信息

100 项与 FIB-116 相关的转化医学

登录后查看更多信息

100 项与 FIB-116 相关的专利（医药）

登录后查看更多信息

1

项与 FIB-116 相关的文献（医药）

2021-06-01·Experimental Dermatology

Anti‐inflammatory effect of amygdalin analogs following topical administration on the TPA‐induced irritant contact dermatitis model in mice

Letter

作者: Gomez, Lluis A. ; Perez, Juan J. ; Porras, Monica

We decided to assess their anti-inflammatory efficacy by topical administration in the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced irritant contact dermatitis model in BALB/c mice.Accordingly, we tested compound FIB-116 in a cream formulation at 3%.In addition, dexamethasone at 0.05% in an acetone/olive oil 4:1 mixture (vehicle) was also included in the study, as pos. control.We conducted a randomized controlled trial using 35 male Balb/c mice that were randomized into five different groups.Groups 1 and 2 were used to assess the efficacy of FIB-116 cream vs. placebo on the TPA model, resp.; groups 3 and 4 were used to assess the efficacy of dexamethasone solution vs. vehicle (control) on the TPA model, resp.; group 5 (blank) only received vehicle.Present results demonstrate a significant moderate anti-inflammatory efficacy of topically administered 3% FIB-116 cream formulation on the TPA-induced irritant contact dermatitis model compared with the pos. control dexamethasone, providing encouraging results to undertake further studies with more sophisticated animal models in the dermatol. field.

100 项与 FIB-116 相关的药物交易

登录后查看更多信息